이전 사이트 이동

For the drug response of in vivo drugs in the clinical stage, utilization of cardiac disease orgaoid models using contractility assay.

The KU Pharm Collaborative AI-Driven Drug Discovery Data Lab Based on Federated Learning collects and manages high-quality pharmaceutical data while ensuring secure data sharing among stakeholders. Furthermore, it aims to enhance AI-driven insights and significantly accelerate drug development by leveraging existing data to independently develop and optimize predictive models for drug discovery.

This project aims to establish an integrated functional verification system for the discovery and development of novel Viroporin-targeting antiviral therapeutics. The ultimate goal is to identify and validate inhibitory compounds against Viroporin proteins, elucidate their mechanisms of action, and build a platform that enables proactive responses to emerging and re-emerging viral infections. The specific objectives include: (1) conducting high-throughput screening (HTS) and functional assays to discover candidate Viroporin inhibitors, (2) performing structural and physiological analyses to define Viroporin activity and its impact on host cells, (3) verifying antiviral efficacy through cellular and molecular assays, and (4) applying Viroporin-focused studies to therapeutic development. The project proceeds in two phases: In Phase I, emphasis will be placed on screening and characterizing Viroporin inhibitors, evaluating their effects on channel function, and assessing physiological outcomes in vitro. In Phase II, validated candidates will undergo functional testing in cell-based systems, including efficacy verification against coronaviruses such as HCoV-OC43 and HCoV-229E, alongside mutational and structural studies (e.g., point/deletion mapping) to optimize target definition and inhibitor design. Through these efforts, the research seeks to deliver a systematic framework for the discovery and development of Viroporin-targeted antivirals that can serve as broad-spectrum and host-directed therapeutic solutions against viral diseases.

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation.

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation.

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation.

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation.

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation.

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation

The purpose of this project is to register compound activity data in the Korea Bio Data Station (K-BDS) and to evaluate the TPP indicators and suitability of the data through feedback from experts across various related fields. It also aims to assess the appropriateness of quality control and to standardize screening information collected from diverse domestic and international institutions through registration forms and indicators. In addition, by introducing and providing consultation on these indicators and standardization methods to domestic researchers involved in compound activity studies, the project seeks to enhance educational and promotional outcomes.

Verified the appropriateness of Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K‑BDS) by gathering input from experts across various domestic fields. We also evaluated data‑quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported outreach by introducing the K‑BDS framework and indicators to domestic researchers, providing consultation, training, and promotional activities.

Verified the appropriateness of Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K‑BDS) by gathering input from experts across various domestic fields. We also evaluated data‑quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported outreach by introducing the K‑BDS framework and indicators to domestic researchers, providing consultation, training, and promotional activities.

This in vitro assay was conducted to validate the efficacy of compounds predicted as dual inhibitors of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) by the BEAR method. Utilizing mitoxantrone, a known P-gp/BCRP substrate, to test intracellular accumulation, predicted compounds from a primary cytotoxicity screen were confirmed as effective dual inhibitors.

Targeting the IL-4 signaling system, which is currently known as the most important therapeutic target for atopic dermatitis, we conducted active ingredient research and safety/efficacy studies on effective natural products secured from previous studies as follows to finally derive therapeutic drug candidates. Established a focused library of seven natural products with confirmed efficacy in transdermal administration derived from previous studies, and selected the most effective natural products for oral administration through in vitro and in vivo screening as candidates and the rest as follow-up materials. After selecting active ingredients that do not activate macrophages (M2) while inhibiting IL-4 expression and pre-blocking in vitro, we evaluated the pharmacological efficacy of the drug candidates by measuring their efficacy against atopic dermatitis and evaluating clinical symptoms, hematological, histopathological, and biological characteristics using various in vivo animal models. Detailed mechanism studies on the effects of candidate natural products and active ingredients on the IL-4 signaling system to identify the exact targets where possible. Complete non-clinical planning according to the drug development roadmap agreed upon with the CRO, and identify candidate natural products that are safe from toxicity that have passed non-clinical tests, leading to materials that can be applied for IND approval.

"The reason why there are still limited cases of successful application of artificial intelligence (AI) in the discovery of innovative drugs is due to a lack of relevant data compared to the complexity of the drug discovery problem. Therefore, to increase the likelihood of success in drug discovery, it is necessary to utilize AI that actively incorporates chemical knowledge, rather than simply applying conventional AI. In this project, we aim to contribute to the advancement of drug discovery platform technology and the discovery of innovative drugs by enhancing algorithms that make active use of AI for predicting binding motifs. 1. AI Model Development and Public Service: Development and enhancement of AI for drug design based on binding motifs (including motif prediction, motif-based virtual screening, motif-based binding optimization, and motif-based property optimization AI), as well as AI model validation and public service. 2. Research to discover active compounds and lead compounds for two disease targets, with the goal of optimizing lead compounds for at least one target, and developing processes and conducting toxicity tests for clinical trial applications."

This project aims to develop AI, machine learning, and deep learning–based JAK2 therapeutic target modeling to identify novel candidates for hematologic and inflammatory diseases. By integrating generative AI with structure-based analysis, the study will design reliable inhibitors with high affinity, selectivity, and stability. Datasets, models, and pipelines will be shared to facilitate adoption by researchers and industry, ultimately enhancing South Korea’s global competitiveness in biopharmaceutical innovation.

The purpose of this project is to register compound activity data in the Korea Bio Data Station (K-BDS) and to evaluate the TPP indicators and suitability of the data through feedback from experts across various related fields. It also aims to assess the appropriateness of quality control and to standardize screening information collected from diverse domestic and international institutions through registration forms and indicators. In addition, by introducing and providing consultation on these indicators and standardization methods to domestic researchers involved in compound activity studies, the project seeks to enhance educational and promotional outcomes.

Chemical Data Quality Management and Utilization

Verified the appropriateness of the Target Product Profile (TPP) indicators for lead and candidate compound data to be registered in the compound data profiling section of the Korea BioData Station (K-BDS) by gathering input from experts across various domestic fields. We also evaluated data quality management compliance and reviewed registration forms and indicators from a range of domestic and international CROs to establish a foundation for suitability and standardization. Furthermore, we supported education and outreach by introducing the center and its indicators to domestic researchers with a high potential to enter the new drug development market, and provided consultation to guide their participation.